Results 211 to 220 of about 123,564 (285)

Assessment of genome evolution in <i>Bifidobacterium adolescentis</i> indicates genetic adaptation to the human gut. [PDF]

open access: yesmSystems
Selleri E   +11 more
europepmc   +1 more source

Oncolytic Probiotics with Molecular Pili for Solid Tumor Therapy

open access: yesAdvanced Science, Volume 13, Issue 19, 2 April 2026.
This study identifies Lactobacillus rhamnosus as an intrinsic oncolytic agent that triggers tumor metabolic collapse via calcium‐dependent ROS bursts. By chemically anchoring collagen‐targeting “molecular pili” to the bacterial surface, the engineered non‐transgenic probiotic (LR@MP) achieves targeted colonization and potent solid tumor suppression ...
Haodong Ge   +14 more
wiley   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

open access: yesAdvanced NanoBiomed Research, Volume 6, Issue 4, April 2026.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari   +5 more
wiley   +1 more source

Polyphenol‐Based Biomaterials Against Cancer Radio/Chemotherapy‐Induced Intestinal Toxicity

open access: yesAdvanced NanoBiomed Research, Volume 6, Issue 4, April 2026.
Radiotherapy/chemotherapy often causes intestinal toxicity, impairing cancer patients’ quality of life and treatment efficacy. Polyphenols protect against this injury via multiple mechanisms, but face oral use limitations. This review outlines their protective mechanisms and delivery challenges, highlighting recent oral delivery advances and future ...
Jixu Lu   +4 more
wiley   +1 more source

Influence of Gut Microbiota on Response to Immune Check Point Inhibitors in MASLD Patients With HCC: Unraveling the Connection

open access: yesCancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment for various cancers, including advanced hepatocellular carcinoma (HCC). However, a significant proportion of patients with HCC, particularly those with metabolic dysfunction‐associated liver disease (MASLD), exhibit resistance to ICI therapy.
Mazen Elsheikh   +9 more
wiley   +1 more source

Metabolic modulation of yogurt fermentation kinetics and acidification by <i>Bifidobacterium</i>-starter culture interactions. [PDF]

open access: yesFront Microbiol
Zhao Z   +13 more
europepmc   +1 more source

The Role of Gut Microbiota and Their Derived Metabolites in Chemotherapy‐Induced Nausea and Vomiting in Ovarian Cancer

open access: yesCancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Objective This study aimed to investigate the relationship between gut microbiota and chemotherapy‐induced nausea and vomiting (CINV) in patients with ovarian cancer undergoing platinum‐based chemotherapy (carboplatin or cisplatin combined with paclitaxel).
Shuiling Zu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy